In the same year, Ziegler and colleagues begun the adventure in developing new therapies based on ELTD1 against mouse glioma models [47] followed by other studies that independently proved the role of this receptor, as molecular target, in glioma therapy [20,25]. This evidence concerns the gene ADGRL4 and glioma.